Noonan syndrome and related disorders: dysregulated RAS-mitogen activated protein kinase signal transduction
1 Departments of Pediatrics and Human Genetics, Mount Sinai School of Medicine, One Gustave Levy Place, Box 1040, New York, NY 10029, USA and 2 Dipartimento di Biologia Cellulare e Neuroscienze, Istituto Superiore di Sanità, Rome 00161, Italy
* To whom correspondence shuld be addressed. Tel: +1 2126596705; Fax: +1 2128492508; Email: bruce.gelb{at}mssm.edu
Received June 30, 2006; Accepted July 26, 2006
Noonan syndrome is a relatively common, genetically heterogeneous Mendelian trait with a pleiomorphic phenotype. Prior to the period covered in this review, missense mutations in PTPN11 had been found to account for nearly 50% of Noonan syndrome cases. That gene encodes SHP-2, a protein tyrosine kinase that plays diverse roles in signal transduction including signaling via the RAS-mitogen activated protein kinase (MAPK) pathway. Noonan syndrome-associated PTPN11 mutations are gain-of-function, with most disrupting SHP-2’s activation–inactivation mechanism. Here, we review recent information that has elucidated further the types and effects of PTPN11 defects in Noonan syndrome and compare them to the related, but specific, missense PTPN11 mutations causing other diseases including LEOPARD syndrome and leukemias. These new data derive from biochemical and cell biological studies as well as animal modeling with fruit flies and chick embryos. The discovery of KRAS missense mutation as a minor cause of Noonan syndrome and the pathogenetic mechanisms of those mutants is discussed. Finally, the elucidation of gene defects underlying two phenotypically related disorders, Costello and cardio-facio-cutaneous syndromes is also reviewed. As these genes also encode proteins relevant for RAS-MAPK signal transduction, all of the syndromes discussed in this article now can be understood to constitute a class of disorders caused by dysregulated RAS-MAPK signaling.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Wagner and M. A. Q. Siddiqui Signal Transduction in Early Heart Development (II): Ventricular Chamber Specification, Trabeculation, and Heart Valve Formation Experimental Biology and Medicine, July 1, 2007; 232(7): 866 - 880. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. van der Burgt, W. Kupsky, S. Stassou, A. Nadroo, C. Barroso, A. Diem, C. P Kratz, R. Dvorsky, M. R. Ahmadian, and M. Zenker Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation J. Med. Genet., July 1, 2007; 44(7): 459 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R Prescott and A. O M Wilkie Genetic aspects of birth defects: new understandings of old problems Arch. Dis. Child. Fetal Neonatal Ed., July 1, 2007; 92(4): F308 - F314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Oliveira, N. Bidere, J. E. Niemela, L. Zheng, K. Sakai, C. P. Nix, R. L. Danner, J. Barb, P. J. Munson, J. M. Puck, et al. NRAS mutation causes a human autoimmune lymphoproliferative syndrome PNAS, May 22, 2007; 104(21): 8953 - 8958. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zenker, K. Lehmann, A. L. Schulz, H. Barth, D. Hansmann, R. Koenig, R. Korinthenberg, M. Kreiss-Nachtsheim, P. Meinecke, S. Morlot, et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations J. Med. Genet., February 1, 2007; 44(2): 131 - 135. [Abstract] [Full Text] [PDF]
|
|